2,253 press releases in English indexed under biotech & pharma.
Investors who lost money in AARD after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
SAN FRANCISCO, Sept. 16, 2026 -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.
VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
New York, New York--(September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may...
JUPITER, Fla., Sept. 16, 2026 -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing a new class of therapies targeting cancer cell mechanics, today announced its selection as a 2026–2027 National Cancer Institute (NCI) Investor Initiatives Showcase...
Donor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two Donor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two
Suvoda wins two PM360 Innovation Awards for Sofia AI assistant for clinical trials, and the Suvoda App, easing burdens for sites, sponsors, and patients.
LONDON and PHILADELPHIA, Sept. 16, 2026 -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.
Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions and decision-making around the role of long-acting injectables (LAIs) in schizophrenia care. This bespoke resource is intended to equip clinicians with key information on LAI benefits and practical guidance for discussing LAIs with their patients.
Novo and Anthropic collaboration will help Novo accelerate the development of new medicines and advance AI-driven software development